Stockreport

CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

CytomX Therapeutics, Inc.  (CTMX) 
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytomx.com
PDF - CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data support [Read more]